Persistency with estrogen replacement therapy among hysterectomized women after the Women’s Health Initiative study

References

• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Isaacs AJ, Drew SV, McPherson K. UK women doctors' use of hormone replacement therapy: 10-year follow up. Climacteric 2005;8:154–61
   PubMed Web of Science ®Google Scholar
• Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy? J Women's Health Gender-based Med 2001;10:343–50
   PubMedGoogle Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Pines A, International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
   PubMed Web of Science ®Google Scholar
• Jalava-Broman J, Makinen J, Ojanlatva A, Jokinen K, Sillanmaki L, Rautava P. Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: follow-up of a normal cohort in Finland. Acta Obstet Gynecol Scand 2011;90:351–7
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 2014;17:252–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769–75
   PubMed Web of Science ®Google Scholar
• Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:543–7
   PubMed Web of Science ®Google Scholar
• Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368–73
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175–87
   PubMed Web of Science ®Google Scholar
• Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880–8
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Kostev K, Hars O, Albert US, Hadji P. Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI Study era. Climacteric 2015;18:737–42
   PubMed Web of Science ®Google Scholar
• Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009. Menopause 2011;18:385–92
   PubMed Web of Science ®Google Scholar
• Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clinical Pharmacol Ther 2009;47:617–26
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012;23:223–31
   PubMed Web of Science ®Google Scholar
• Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012;50:315–22
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 2014;25:2721–8
   PubMed Web of Science ®Google Scholar
• Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies – report of the ISPOR Task Force on Retrospective Databases. Value Health 2003;6:90–7
   PubMed Web of Science ®Google Scholar
• Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Safety 2007;16:17–27
   PubMed Web of Science ®Google Scholar
• Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA 2003;289:3241–2
   PubMed Web of Science ®Google Scholar
• Gavin NI, Thorp JM, Ohsfeldt RL. Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri. Menopause 2001;8:377–83
   PubMed Web of Science ®Google Scholar
• Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the Women's Health Initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495–9
   PubMed Web of Science ®Google Scholar
• Bretler DM, Hansen PR, Abildstrom SZ, et al. Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study. Br J Clin Pharmacol 2011;71:105–15
   PubMed Web of Science ®Google Scholar
• Buick DL, Crook D, Horne R. Women's perceptions of hormone replacement therapy: risks and benefits (1980–2002). A literature review. Climacteric 2005;8:24–35
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997;28:137–45
   PubMed Web of Science ®Google Scholar
• Oren A. Motives for initiation, temporary discontinuation, and permanent discontinuation of hormone replacement therapy use among Norwegian women. Maturitas 2009;64:33–7
   PubMed Web of Science ®Google Scholar
• Corrado F, D'Anna R, Caputo F, Cannata ML, Zoccali MG, Cancellieri F. Compliance with hormone replacement therapy in postmenopausal Sicilian women. Eur J Obstet Gynecol Reprod Biol 2005;118:225–8
   PubMed Web of Science ®Google Scholar
• Buhling KJ, von Studnitz FS, Jantke A, Eulenburg C, Mueck AO. Attitude of German gynecologists towards prescribing HRT before and after the WHI study. Climacteric 2012;15:326–31
   PubMed Web of Science ®Google Scholar
• Panay N, Hamoda H, Arya R, Savvas M; British Menopause Society, Women's Health Concern. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19:59–68
   PubMedGoogle Scholar